Amgen (AMGN) Non-Current Deferred Tax Liability (2013 - 2026)
Amgen (AMGN) posted quarterly Non-Current Deferred Tax Liability of $1.3 billion for Q1 2026, down 10.99% year-over-year from $1.5 billion in Q1 2025, and down 1.61% quarter-over-quarter from $1.4 billion in Q4 2025.
Amgen (AMGN) Non-Current Deferred Tax Liability (2013 - 2026) Analysis & Trends
Amgen's Non-Current Deferred Tax Liability history runs 13 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 10.99% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 10.99% YoY), while the FY2025 annual figure was $1.4 billion, down 15.47% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $1.3 billion, down from $1.4 billion in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $2.4 billion in Q4 2023, with the low at $1.3 billion in Q1 2026.
- The 5-year median for Non-Current Deferred Tax Liability is $1.6 billion (2024), against an average of $1.7 billion.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability rose 25.48% in 2023, then plunged 31.35% in 2024.
- Amgen's Non-Current Deferred Tax Liability stood at $1.9 billion in 2022, then gained by 25.48% to $2.4 billion in 2023, then slumped by 31.35% to $1.6 billion in 2024, then slipped by 15.47% to $1.4 billion in 2025, then dropped by 1.61% to $1.3 billion in 2026.
- Business Quant data shows AMGN's Non-Current Deferred Tax Liability at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Bn |
| Jun 30, 2026 | 1.30 Bn |
| Mar 31, 2026 | 1.34 Bn |
| Mar 31, 2026 | 1.34 Bn |
| Dec 31, 2025 | 1.37 Bn |
| Dec 31, 2025 | 1.37 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.39 Bn |
| Jun 30, 2025 | 1.39 Bn |
| Mar 31, 2025 | 1.51 Bn |
| Mar 31, 2025 | 1.51 Bn |
| Dec 31, 2024 | 1.62 Bn |
| Dec 31, 2024 | 1.62 Bn |
| Sep 30, 2024 | 1.71 Bn |
| Sep 30, 2024 | 1.71 Bn |
| Jun 30, 2024 | 1.78 Bn |
| Jun 30, 2024 | 1.78 Bn |
| Mar 31, 2024 | 1.86 Bn |
| Mar 31, 2024 | 1.86 Bn |